{
    "name": "nivolumab/relatlimab",
    "comment": "Rx",
    "other_names": [
        "Opdualag",
        "nivolumab/relatlimab-rmbw"
    ],
    "classes": [
        "LAG-3 Inhibitors",
        "PD-1/PD-L1 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/opdualag-nivolumab-relatlimab-4000249",
    "pregnancy": {
        "common": [
            "Based on mechanism of action, fetal harm may occur when administered to pregnant females",
            "No data are available on use in pregnant females to evaluate drug-associated risks",
            "Advise patients of potential risks to fetus",
            "Verify pregnancy status before initiating",
            "Human IgG4 is known to cross the placenta; therefore, nivolumab and relatlimab may transmit from mother to developing fetus; effects are likely to be greater during second and third trimesters of pregnancy"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment with nivolumab and for at least 5 months following last dose of therapy"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Nivolumab: IV administration (administered twice weekly during organogenesis) in monkeys resulted in a non-dose-related increase in spontaneous abortion and increased neonatal death",
                    "Relatlimab: No animal data are available; when anti-LAG-3 antibodies were administered beginning on gestation day 6 in mice using syngeneic and allogeneic breeding models, no maternal or developmental effects were observed"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of nivolumab and relatlimab in human milk, effects on breastfed infants, or effects on milk production",
            "Advise patients not to breastfeed during treatment and for at least 5 months after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe infusion-related reactions can occur; discontinue if severe or life-threatening infusion reactions occurs",
                "Fatal or serious graft-versus-host disease (GVHD) can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after treatment with a PD-1/PD-L1 receptor blocking antibody; closely monitor for evidence of GVHD and intervene promptly; consider benefit versus risks of treatment with a PD-1/PD-L1 receptor blocking antibody after allogeneic HSCT",
                "May cause fetal harm when administered to pregnant females"
            ],
            "specific": [
                {
                    "type": "Immune-mediated adverse reactions",
                    "description": [
                        "Immune-mediated adverse reactions (IMARs), which may be severe or fatal, can occur",
                        "IMARs can manifest during treatment and after discontinuation",
                        "Closely monitor for symptoms and signs that may be clinical manifestations of underlying IMARs; evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment",
                        "If IMARs are suspected, initiate appropriate workup to exclude alternative etiologies, including infection; promptly institute medical management, including specialty consultation as appropriate",
                        "May cause immune-mediated pneumonitis; incidence of pneumonitis is higher in patients who have received prior thoracic radiation and treated with other PD-1/PD-L1 blocking antibodies",
                        "Immune-mediated encephalitis can occur; withhold therapy in patients with new-onset moderate-to-severe neurologic signs or symptoms and evaluate to rule out infectious or other causes of moderate-to-severe neurologic deterioration",
                        "Other clinically significant and potentially fatal IMARs (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis, hepatitis, nephritis) can occur after discontinuation",
                        "Immune-mediated endocrinopathies",
                        "Immune-mediated hypophysitis; monitor",
                        "Immune-mediated hypothyroidism and hyperthyroidism reported; monitor for changes in thyroid function and initiate thyroid hormone replacement as needed; administer hormone replacement therapy for hypothyroidism; initiate medical management for control of hyperthyroidism",
                        "Adrenal insufficiency may occur; monitor for signs and symptoms of adrenal insufficiency during and after treatment",
                        "May cause type 1 diabetes mellitus; monitor for hyperglycemia",
                        "Hypothyroidism can follow hyperthyroidism",
                        "Thyroiditis may not lead to permanent discontinuation and may be reinitiated after symptoms improvement without reoccurrence",
                        "Type 1 diabetes mellitus may present with diabetic ketoacidosis; initiate treatment with insulin as clinically indicated",
                        "Immune-mediated skin reactions",
                        "May cause immune-mediated rash, including SJS, and TEN; for symptoms or signs of SJS or TEN, withhold therapy and refer patient for specialized care for assessment and treatment",
                        "Immune-mediated colitis",
                        "Immune-mediated colitis reported, defined as requiring use of corticosteroids and no clear alternate etiology; common symptom in definition of colitis reported to be diarrhea",
                        "Cytomegalovirus infection/reactivation also reported in patients with corticosteroid-refractory immune-mediated colitis",
                        "For corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Musculoskeletal pain",
            "percent": "45"
        },
        {
            "name": "Fatigue",
            "percent": "39"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "37"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "32"
        },
        {
            "name": "Increased AST",
            "percent": "30"
        },
        {
            "name": "Rash",
            "percent": "28"
        },
        {
            "name": "Increased ALT",
            "percent": "26"
        },
        {
            "name": "Pruritus",
            "percent": "25"
        },
        {
            "name": "Diarrhea",
            "percent": "24"
        },
        {
            "name": "Decreased sodium",
            "percent": "24"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "19"
        },
        {
            "name": "Increased creatinine",
            "percent": "19"
        },
        {
            "name": "Headache",
            "percent": "18"
        },
        {
            "name": "Nausea",
            "percent": "17"
        },
        {
            "name": "Hypothyroidism",
            "percent": "17"
        },
        {
            "name": "Decreased appetite",
            "percent": "15"
        },
        {
            "name": "Cough",
            "percent": "15"
        },
        {
            "name": "Vitiligo",
            "percent": "15"
        },
        {
            "name": "Adrenal sufficiency",
            "percent": "15"
        },
        {
            "name": "Myocarditis",
            "percent": "15"
        },
        {
            "name": "Hepatitis",
            "percent": "15"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "4.2"
        },
        {
            "name": "Increased ALT",
            "percent": "3.2"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "2.7"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "2.5"
        },
        {
            "name": "Increased AST",
            "percent": "2.3"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Rash",
            "percent": "1.4"
        },
        {
            "name": "Decreased sodium",
            "percent": "1.2"
        },
        {
            "name": "Nausea",
            "percent": "0.6"
        },
        {
            "name": "Decreased appetite",
            "percent": "0.6"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "0.6"
        },
        {
            "name": "Headache",
            "percent": "0.3"
        },
        {
            "name": "Cough",
            "percent": "0.3"
        }
    ]
}